Abstracts Posters SICOT-SOF meeting Gothenburg 2010 _2_

Poster
Topic: Arthroplasty - Hip
Abstract number: 23441
THE USE AND COMPLIANCE OF RIVAROXABAN FOR
THROMBOPROPHYLAXIS IN ELECTIVE HIP ARTHROPLASTY
Sioned PHILLIPS, Benedict ROGERS, Khalid DRABU
East Surrey Hospital, Redhill (UNITED KINGDOM)
Introduction: The peak incidence of venous thromboembolism is at 21 days following
hip arthroplasty and current guidelines proposed that thromboprophylaxis should
continue for 4 weeks post surgery. This study compares the length of treatment and
satisfaction for patients prescribed low molecular weight heparin (LMWH) or
rivaroxaban, a new oral factor Xa inhibitor, following elective hip arthroplasty.
Methods: A prospective study was performed of one hundred consecutive hip
replacements with fifty patients prescribed 10mg once daily of oral rivaroxaban and
fifty prescribed 40mg once daily of subcutaneous enoxaparin. Thromboprophylaxis
was planned for 6 weeks in both groups. From the medical records and patient
survey, the compliance, satisfaction and complications for both groups was
quantified. Results: The prescription of rivaroxaban was associated with greater
compliance over the first four weeks following surgery (88 % vs 5%, p